Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs
Jacob Meacham Smith, Josiah D. Rich – 21 January 2017
Introducing the AASLD president: Anna S.F. Lok
Grace L. Su, Robert J. Fontana – 21 January 2017
Treatment of hepatitis C virus infection in children: Time for action
Giuseppe Indolfi, Lorenzo D'Antiga – 20 January 2017
Reply
Àngels Escorsell, Oana Pavel, Andrés Cárdenas, Rosa Morillas, Elba Llop, Càndid Villanueva, Juan Càrlos Garcia‐Pagan, Jaime Bosch – 20 January 2017
The membrane‐bound O‐acyltransferase domain‐containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B
Khaled Thabet, Henry Lik Yuen Chan, Salvatore Petta, Alessandra Mangia, Thomas Berg, Andre Boonstra, Willem P. Brouwer, Maria Lorena Abate, Vincent Wai‐Sun Wong, Maiiada Nazmy, Janett Fischer, Christopher Liddle, Jacob George, Mohammed Eslam – 20 January 2017 – Chronic hepatitis B (CHB) is characterized by hepatic inflammation that promotes progression to cirrhosis and predisposes to the development of hepatocellular carcinoma (HCC). Subtle interindividual genetic variation as well as viral and environmental factors interact to determine disease progression between individuals.
Thromboelastography and blood product usage in cirrhosis with severe coagulopathy
Antoni Sabate, Annabel Blasi – 19 January 2017
Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic
Iliana Doycheva, Kymberly D. Watt, Naim Alkhouri – 19 January 2017 – Nonalcoholic fatty liver disease (NAFLD) is a significant health burden in adolescents and young adults (AYAs) which has substantially risen in prevalence over the last decades. The occurrence of NAFLD parallels high rates of obesity and metabolic syndrome in this age group, with unhealthy lifestyle also playing an independent role. Genetic factors, sex, and ethnicity should be considered in a risk stratification model.
Potential effect of lamivudine‐induced S gene mutations on liver‐related pathogenesis in hepatitis D virus infection
Anders Boyd, Patrick Miailhes, Karine Lacombe, Fabien Zoulim – 19 January 2017
Reply
Salvatore Petta, Vincent Way‐Sun Wong, Victor de Ledinghen – 19 January 2017
Do we need controlled attenuation parameter adjustment for fibrosis estimation in nonalcoholic fatty liver disease patients?
Thomas Karlas, Sebastian Beer, Jonas Babel, Harald Busse, Alexander Schaudinn, Nicolas Linder, Johannes Wiegand, David Petroff – 19 January 2017